Objectives: The aim of our study was to identify factors associated with persistent low-level viraemia (LLV) in HIV-infected patients under suppressive antiretroviral therapy and to assess the virological outcome of these patients.
Introduction
The objective of combined antiretroviral therapy (cART) is to reach and maintain plasma virological suppression ,50 copies/mL. 1 Several studies using ultra-sensitive techniques evidenced residual low-level viraemia (LLV) in a high proportion of virologically suppressed patients under cART. 2 -6 In clinical trials and international recommendations, the level of 50 copies/mL is the current accepted threshold for virological suppression. Upgraded commercial assays are now able to detect viral loads ,50 copies/mL, such as the COBAS AmpliPrep/COBAS TaqMan HIV-1 v2.0 assay with a limit of detection of 20 copies/mL. Thus, it is expected that some patients display HIV-1 RNA values between 20 and 50 copies/mL. However, the relevance in the clinical setting of LLV between 20 and 50 copies/mL is still uncertain.
The aim of our study was to identify factors associated with the detection of persistent LLV, defined as several HIV-1 RNA values between 20 and 50 copies/mL, in patients receiving stable cART and to assess the virological outcome of these patients.
Patients and methods

Study patients
This was a longitudinal study among the 4820 patients followed in the clinical unit of infectious diseases of Hô pital Bichat-Claude Bernard, Patients were eligible for inclusion in Period 1 if they met the following inclusion criteria: (i) stable cART for at least 6 months before study inclusion; (ii) all HIV-1 RNA values ,50 copies/mL during Period 1; and (iii) at least three HIV-1 RNA determinations during Period 1. Two groups of patients were defined: group LLV2 included patients with all HIV-1 RNA values ,20 copies/mL during Period 1; and group LLV+ included patients with at least two HIV-1 RNA values between 20 and 50 copies/mL, consecutive or not, during Period 1. Patients with an isolated HIV-1 RNA value between 20 and 50 copies/mL during Period 1 were excluded from the study.
The study protocol was approved by an institutional ethics review board (Saint-Germain en Laye, France) and all patients provided their written informed consent.
Measurement of plasma HIV-1 RNA level
HIV-1 RNA quantification assay was performed using the new COBAS AmpliPrep COBAS TaqMan HIV-1 test, version 2.0 (CAP/CTM v2.0) (Roche Molecular Systems, Branchburg, NJ, USA) with the lower quantification limit of 20 copies/mL. No repeat of the HIV-1 RNA quantification assay was performed.
In order to assess the occurrence of transient detectable viraemia .50 copies/mL and ,1000 copies/mL a 'blip ratio' was defined as (number of HIV-1 RNA values .50 copies/mL)/(number of HIV-1 RNA determinations during period of interest). The blip ratio was calculated: (i) before study inclusion during all the time the patient received ongoing cART; and (ii) during Period 2. By definition, no detectable viraemia .50 copies/mL was allowed during Period 1.
Genotypic resistance tests
Bulk sequencing of protease and reverse transcriptase was performed according to the complete sequencing procedures and primer sequences described at www.hivfrenchresistance.org. Resistance mutations were identified according to the IAS-USA list. 7 
Virological outcome
To assess the impact of LLV on virological outcome, all patients included in Period 1 were further followed up during Period 2. All HIV-1 RNA values available during Period 2 were collected. As in Period 1, only patients with at least three HIV-1 RNA determinations during this period were included in Period 2. Virological failure was defined as two consecutive HIV-1 RNA values .50 copies/mL. Several outcomes were assessed during Period 2: (i) proportion of patients with all HIV-1 RNA values ,20 copies/mL; (ii) proportion of patients with LLV; and (iii) proportion of patients with virological failure.
Statistical analysis
Continuous variables were expressed as medians and IQRs, and categorical variables were expressed as numbers and percentages. To compare clinical and virological characteristics, at study inclusion or before, of patients in group LLV2 or LLV+ of Period 1, the Wilcoxon test was used for continuous variables and Fisher's exact test was used for categorical variables in the univariate analysis. Variables with P, 0.2 in univariate analysis were included in a multivariate logistic regression model using a backward elimination procedure and a significance level of P¼0.05. Two-way interactions were studied between significant variables in multivariate analysis; when interactions were significant at the level of P¼0.05 they were retained in the final multivariate model.
For Period 2, the occurrence of virological failure was compared between group LLV2 and group LLV+ using Fisher's exact test and the blip ratio using the Wilcoxon test.
All tests were two-sided at the 0.05 significance level. Analyses were performed with SAS statistical software (version 9.2; SAS Institute, Cary, NC, USA).
Results
Factors associated with persistent LLV
During Period 1, 656 patients fulfilled the inclusion criteria. Among them, 618 patients (94.2%) displayed all HIV-1 RNA values ,20 copies/mL and were included in group LLV2. The 38 remaining patients (5.8%) had at least two HIV-1 RNA values between 20 and 50 copies/mL and were included in group LLV+. The median number of HIV-1 RNA determinations was similar in both groups (n¼ 4).
The characteristics at study inclusion of the patients in both groups and the results of univariate analysis are reported in Table 1 . No differences between the LLV2 and LLV+ groups could be observed in the therapeutic history of the patients (Table 1) . Neither the duration of virological suppression nor the nature of the ongoing cART regimen differed significantly between the two groups. A protease inhibitor (PI)-based regimen was received by 49% and 50% of patients in groups LLV2 and LLV+, respectively. In the univariate analysis, the following factors were associated with being in group LLV+: age (P ¼ 0.04); CDC clinical stage at study inclusion (P ¼ 0.004); CDC clinical stage at time of initiation of the first cART regimen (P ¼ 0.006); HIV-1 RNA value at initiation of the ongoing cART (P ¼ 0.02); CD4 cell count at initiation of the ongoing cART (P ¼ 0.02); duration of ongoing cART (P ¼ 0.047); and a higher blip ratio during ongoing cART before study inclusion (P ¼ 0.007).
In the multivariate analysis, only CDC stage B/C at study inclusion (OR 2.9; 95% CI 1.4 -5.9; P ¼0.003) and a higher blip ratio (OR 0.9; 95% CI 0.9 -1.0; P ¼ 0.001) were independently associated with persistent LLV.
No significant difference in CD4 cell count variations during Period 1 was observed between LLV2 and LLV+ patients (median change in CD4 during Period 1: 11 versus 53 cells/mm 3 in groups LLV2 and LLV+, respectively).
Virological characteristics in study groups
Virological analysis was performed in order to evidence possible differences in viral characteristics between viruses from patients of groups LLV2 and LLV+.
Genotypic resistance tests were available before study inclusion in 135 patients in group LLV2 and 24 patients in group LLV+. No significant difference was evidenced in the proportion of HIV-1 'non-B' subtypes between the two groups: 66% in group LLV2 versus 67% in group LLV+ (P ¼ 1.0). The median number of resistance-associated mutations was similar in both groups (two versus one in groups LLV2 and LLV+, respectively; P ¼ 0.7), with no differences among the antiretroviral drug classes (data not shown).
Charpentier et al.
Virological outcome of patients with persistent LLV
During Period 2, 413 (66.8%) patients from group LLV2 and 25 (65.8%) from group LLV+ were assessed.
The proportion of patients experiencing virological failure was not significantly different between groups LLV2 and LLV+ (4% versus 8%, respectively; P ¼ 0.32) ( Table 2 ). The median HIV-1 RNA value at the time of failure was 250 copies/mL (IQR 94 -1342) in group LLV2 and 88 copies/mL in group LLV+ (IQR 84 -123). During Period 2, the blip ratio was not different between the two groups. The follow-up showed that 267 (65%) and 11 (44%) patients displayed all HIV-1 RNA values ,20 copies/mL in groups LLV2 and LLV+, respectively ( Table 2 ). The proportion of patients experiencing LLV was higher in group LLV+ (16%, n¼ 4) when compared with group LLV2 (2%, n¼ 7) (P ¼0.002).
Discussion
The new commercial HIV-1 RNA quantification assays led to the identification of patients with HIV-1 RNA values between 20 and 
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50 copies/mL, but there is no standard therapeutic monitoring for this situation. In the present study, based on the follow-up of 656 patients under stable suppressive cART, detection of persistent LLV between 20 and 50 copies/mL was infrequent, observed in 5.8% of our population. The detection of persistent LLV was not significantly linked to the nature of the antiretroviralbased regimen or to CD4 cell count or HIV-1 RNA value at initiation of the first-line regimen or ongoing treatment. However, CDC clinical stage B/C was associated with higher occurrence of LLV. In addition, patients displaying persistent LLV more frequently had a past history of detectable viraemia .50 copies/mL before study inclusion than patients with fully suppressed replication. Regarding HIV-1 subtype and the number of resistance-associated mutations, no significant difference could be observed between viruses from patients with LLV and those from fully suppressed patients. Finally, LLV does not seem to have a deleterious effect on immune status. Taken together, these findings likely suggest that the detection of persistent LLV between 20 and 50 copies/mL seems not to be a random biological phenomenon. A higher prevalence of LLV (25.3%) was observed in a previous study assessing the prevalence of HIV-1 RNA values between 20 and 50 copies/mL in virologically suppressed patients (n¼91). 8 This difference might be explained by the study design: a transverse study with only one HIV-1 RNA measure in the study of Pascual-Pareja et al. 8 compared with a longitudinal study with at least three HIV-1 RNA determinations over a 1 year period in our study. In the study of Pascual-Pareja et al., 8 factors associated with the detection of HIV-1 RNA between 20 and 50 copies/mL were HIV-1 RNA level before initial cART and time on cART, different from those observed in our study.
Previous studies have reported an association between the level of residual viraemia and the nature of the antiretroviral-based regimen. Thus, two studies showed that the use of non-nucleoside reverse transcriptase inhibitors was associated with lower levels of residual viraemia when compared with the use of PIs, 4 -6 and another study showed a higher efficacy of nevirapine than efavirenz in achieving an HIV-1 RNA level ,1 copy/mL. 5 In the present study, we did not demonstrate an association between the nature of cART and the detection of LLV. However, we assessed a different stratum of viral replication, between 20 and 50 copies/mL, probably reflecting a distinct physiopathological mechanism from viral replication at the level of ,3 copies/mL, which might explain the differences in results.
The phenomenon of LLV can result from ongoing residual viral replication or from viral release mechanisms. 9 Furthermore, quantification assays might also drive this phenomenon, by the significant widening of the coefficients of variation at the lower limits of the quantitative range. 10 Thus, the Department of Health and Human Services (DHHS, USA) guidelines recently reported that for the purposes of clinical trials the AIDS Clinical Trials Group (ACTG) currently defines virological failure as a confirmed viral load .200 copies/mL, which eliminates most cases of apparent viraemia caused by blips or assay variability. 11 We assessed the virological outcome of the 38 patients displaying persistent LLV during the year following the detection of LLV between 20 and 50 copies/mL. This small sample size might lead to a lack of statistical power; however, we showed no difference in the frequency of virological failure during the year of follow-up in patients with LLV compared with patients with sustained HIV-1 RNA values ,20 copies/mL. In addition, 44% of the patients with LLV during the inclusion period displayed all HIV-1 RNA values ,20 copies/mL during the follow-up period and 16% still displayed LLV. A previous study, assessing the significance of LLV between 12 and 40 copies/mL (n¼ 69 patients), similarly showed no significant association with the development of virological failure when compared with patients with undetectable HIV-1 RNA values (i.e. ,12 copies/mL). 12 However, patients with detectable LLV in this latter study were significantly less likely to achieve subsequent virological suppression. 12 Conversely, a recent study reported the association between a very low level of viral replication (.3 copies/mL) and the risk of virological failure. 13 One limitation of our study could be the duration of follow-up, which was 1 year. We can hypothesize that a longer period of follow-up might have led to evidence of a higher number of virological failures in the LLV+ group.
In conclusion, persistent LLV was infrequent in our series and the 1 year follow-up did not evidence a higher rate of virological failure than in patients with all HIV-1 RNA values ,20 copies/mL. LLV seems to be a transient and dynamic phenomenon, with 40% of patients shifting from LLV status to complete viral load suppression. For the moment, no selection of resistance mutations has been described in the literature at LLV ,50 copies/mL. Indeed, selection of resistance mutations has been described only in case of persistent viraemia .50 copies/mL. 14, 15 These results suggest that LLV, in patients with no viral blip .50 copies/mL, should not drive therapeutic modifications. However, clinical trials to assess the potential benefit of therapeutic interventions in patients exhibiting persistent LLV between 20 and 50 copies/mL are needed to establish the management of these patients. 
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